These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Nonspecific osteomyelitis in childhood and adolescence. The contribution of imaging diagnosis]. Urso S; Pacciani E; Fariello G; Colajacomo M; Fassari FM; Randisi F; Certo A; Liberatore M; Pagnotta G Radiol Med; 1995 Sep; 90(3):212-8. PubMed ID: 7501824 [TBL] [Abstract][Full Text] [Related]
8. Radiopharmacology of inhaled 133Xe in skeletal sites containing deposits of Gaucher cells. Castronovo FP; McKusick KA; Doppelt SH; Barton NW Nucl Med Biol; 1993 Jul; 20(5):707-14. PubMed ID: 8358357 [TBL] [Abstract][Full Text] [Related]
9. Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT. Payne JK; Trivedi MH; Devous MD J Nucl Med; 1996 Oct; 37(10):1735-40. PubMed ID: 8862321 [TBL] [Abstract][Full Text] [Related]
10. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours. Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180 [TBL] [Abstract][Full Text] [Related]
11. Discordant technetium-99m-MIBI and technetium-99m-HMPAO uptake of recurrent occipital meningioma on brain SPECT images. Shih WJ; Lee JK; Milan P J Nucl Med; 1996 Jul; 37(7):1183-5. PubMed ID: 8965195 [TBL] [Abstract][Full Text] [Related]
14. Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? A review of the literature. Mikosch P; Kohlfürst S; Gallowitsch HJ; Kresnik E; Lind P; Mehta AB; Hughes DA Nuklearmedizin; 2008; 47(6):239-47. PubMed ID: 19057797 [TBL] [Abstract][Full Text] [Related]
15. Scintigraphic findings in Gaucher's disease. Israel O; Jerushalmi J; Front D J Nucl Med; 1986 Oct; 27(10):1557-63. PubMed ID: 3760980 [TBL] [Abstract][Full Text] [Related]
16. Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements. Gumuser G; Parlak Y; Topal G; Aras F; Ruksen E; Sayit E Nucl Med Commun; 2009 Jun; 30(6):445-8. PubMed ID: 19357550 [TBL] [Abstract][Full Text] [Related]
17. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Hermann G; Goldblatt J; Levy RN; Goldsmith SJ; Desnick RJ; Grabowski GA AJR Am J Roentgenol; 1986 Nov; 147(5):943-8. PubMed ID: 3490167 [TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
19. Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Lorberboym M; Vallabhajosula S; Lipszyc H; Pastores G Clin Genet; 1997 Jul; 52(1):7-11. PubMed ID: 9272706 [TBL] [Abstract][Full Text] [Related]
20. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease. Erba PA; Minichilli F; Giona F; Linari S; Dambrosia J; Pierini A; Filocamo M; Di Rocco M; Buffoni F; Brady RO; Mariani G J Nucl Med; 2013 Oct; 54(10):1717-24. PubMed ID: 23990684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]